News >

NICE Recommends Midostaurin for FLT3+ AML

Jason M. Broderick @jasoncology
Published: Friday, May 04, 2018

Paresh Vyas, MD, PhD
Paresh Vyas, MD, PhD
The National Institute for Health and Care Excellence (NICE) has authorized the use of midostaurin (Rydapt) in combination with standard chemotherapy for the treatment of patients with newly diagnosed FLT3-positive acute myeloid leukemia (AML), according to Novartis, the manufacturer of the multikinase inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x